Background:Liver cancer is one of the major causes of cancer-related deaths globally.Cancer cell stem-ness and chemotherapy resistance contribute to the high mortality.Although evidence indicates that the alpha subuni...Background:Liver cancer is one of the major causes of cancer-related deaths globally.Cancer cell stem-ness and chemotherapy resistance contribute to the high mortality.Although evidence indicates that the alpha subunit of protein kinase 2(CK2α)is involved in several human cancers,its function in liver cancer remains unknown.In the present study,we aimed to elucidate the role of CK2αin liver cancer.Methods:We examined the role of CK2αregulation in stemness and chemotherapy resistance capacity of liver cancer cells.MTT assays,tumor sphere formation assays,RT-PCR,flow cytometry,Western blotting assay,clonogenicity assay,matrigel invasion assay and bioinformatics were conducted in this study.Results:CK2αexpression in the liver cancer tissues was notably upregulated compared with that in the corresponding non-tumorous tissues.The overexpression of CK2αpromoted tumor sphere formation,increased the percentage of CD133(+)and side population cells,caused the resistance of liver cancer cells to 5-FU treatment,increased the expression levels of NANOG,OCT4,SOX2,Gli1 and Ptch1,and enhanced the ability of CD133(+)cell clone formation and invasion.Consistently,the downregulation of CK2αhad the opposite effects.CK2αsilencing inhibited the Hedgehog pathway by reducing the expression of Gli1 and Ptch1.Mechanistically,CK2αregulation on liver cancer cell stemness and chemotherapy resistance was found to be involved in the Hedgehog signaling pathway.Conclusions:Our study may bring some new insights into the occurrence of liver cancer.Furthermore,these findings suggest that targeting CK2αmay be a novel therapeutic strategy for patients with liver cancer.展开更多
背景与目的:三磷酸腺苷结合盒转运体成员ABCG2(ATP-binding cassette superfamily G member2)是源于造血干细胞的标志物之一,其在神经胶质瘤发生发展相关组织和细胞中的表达情况还不清楚。本研究检测ABCG2在不同恶性程度人脑胶质瘤组织...背景与目的:三磷酸腺苷结合盒转运体成员ABCG2(ATP-binding cassette superfamily G member2)是源于造血干细胞的标志物之一,其在神经胶质瘤发生发展相关组织和细胞中的表达情况还不清楚。本研究检测ABCG2在不同恶性程度人脑胶质瘤组织标本、裸小鼠移植瘤标本、体外细胞系球体和胶质瘤干细胞球体中的表达情况并分析其意义。方法:制作布有不同恶性程度人脑胶质瘤组织标本、裸小鼠移植瘤标本、体外细胞系球体和胶质瘤干细胞球体等的组织芯片,用免疫组化方法检测ABCG2在组织芯片中的表达情况。结果:在71例人脑胶质瘤组织标本中ABCG2的阳性率为26.8%,其中Ⅰ级11.1%,Ⅱ级8.0%,Ⅲ级43.5%,Ⅳ级42.9%;Ⅰ～Ⅱ级与Ⅲ～Ⅳ级相比差异具有统计学意义(%2=10.710,P=0.001)。在神经干细胞、裸小鼠移植瘤、胶质瘤干细胞球体表达率为100%。在多种正常组织中亦有不同程度的表达。在胶质瘤临床标本中ABCG2阳性细胞呈亲血管分布。结论:ABCG2在胶质瘤干细胞、恶性程度高的胶质瘤组织标本和移植瘤组织中高表达,并且呈亲血管分布。展开更多
目的:明确结直肠癌组织中ABCG2(ATP-binding cassette superfamily G member 2,ABCG2)的表达及其与患者临床病理特征、以伊立替康(CPT-11)为基础化疗疗效的相关性,从而为结直肠癌患者实现个体化治疗提供理论依据。方法:筛选1996年1月至2...目的:明确结直肠癌组织中ABCG2(ATP-binding cassette superfamily G member 2,ABCG2)的表达及其与患者临床病理特征、以伊立替康(CPT-11)为基础化疗疗效的相关性,从而为结直肠癌患者实现个体化治疗提供理论依据。方法:筛选1996年1月至2011年12月于北京大学肿瘤医院行CPT-11化疗的晚期结直肠癌患者,收集患者完整病史资料及肿瘤组织样本。用免疫组织化学的方法检测样本中ABCG2蛋白表达情况。分析ABCG2蛋白表达与患者临床病理特征、CPT-11化疗疗效的相关性。结果:1)免疫组织化学染色显示ABCG2在结直肠癌组织中表达阳性率达93.2%,癌旁正常肠黏膜ABCG2蛋白阳性表达率为43.6%,癌组织较癌旁正常黏膜组织的表达水平明显增高(P<0.05)。ABCG2表达与患者年龄、性别、病理分化程度、病变部位、肝转移均无明显相关性。2)ABCG2蛋白表达与CPT-11化疗疗效无显著相关(P>0.05)。结论:在应用伊立替康为基础方案化疗的结直肠癌患者中,癌组织中ABCG2蛋白表达水平与患者化疗疗效无明显相关。展开更多
基金supported by grants from the National Natu-ral Science Foundation of China (81602589 and 81601692)345 Talent Program of Shengjing Hospital
文摘Background:Liver cancer is one of the major causes of cancer-related deaths globally.Cancer cell stem-ness and chemotherapy resistance contribute to the high mortality.Although evidence indicates that the alpha subunit of protein kinase 2(CK2α)is involved in several human cancers,its function in liver cancer remains unknown.In the present study,we aimed to elucidate the role of CK2αin liver cancer.Methods:We examined the role of CK2αregulation in stemness and chemotherapy resistance capacity of liver cancer cells.MTT assays,tumor sphere formation assays,RT-PCR,flow cytometry,Western blotting assay,clonogenicity assay,matrigel invasion assay and bioinformatics were conducted in this study.Results:CK2αexpression in the liver cancer tissues was notably upregulated compared with that in the corresponding non-tumorous tissues.The overexpression of CK2αpromoted tumor sphere formation,increased the percentage of CD133(+)and side population cells,caused the resistance of liver cancer cells to 5-FU treatment,increased the expression levels of NANOG,OCT4,SOX2,Gli1 and Ptch1,and enhanced the ability of CD133(+)cell clone formation and invasion.Consistently,the downregulation of CK2αhad the opposite effects.CK2αsilencing inhibited the Hedgehog pathway by reducing the expression of Gli1 and Ptch1.Mechanistically,CK2αregulation on liver cancer cell stemness and chemotherapy resistance was found to be involved in the Hedgehog signaling pathway.Conclusions:Our study may bring some new insights into the occurrence of liver cancer.Furthermore,these findings suggest that targeting CK2αmay be a novel therapeutic strategy for patients with liver cancer.
文摘背景与目的:三磷酸腺苷结合盒转运体成员ABCG2(ATP-binding cassette superfamily G member2)是源于造血干细胞的标志物之一,其在神经胶质瘤发生发展相关组织和细胞中的表达情况还不清楚。本研究检测ABCG2在不同恶性程度人脑胶质瘤组织标本、裸小鼠移植瘤标本、体外细胞系球体和胶质瘤干细胞球体中的表达情况并分析其意义。方法:制作布有不同恶性程度人脑胶质瘤组织标本、裸小鼠移植瘤标本、体外细胞系球体和胶质瘤干细胞球体等的组织芯片,用免疫组化方法检测ABCG2在组织芯片中的表达情况。结果:在71例人脑胶质瘤组织标本中ABCG2的阳性率为26.8%,其中Ⅰ级11.1%,Ⅱ级8.0%,Ⅲ级43.5%,Ⅳ级42.9%;Ⅰ～Ⅱ级与Ⅲ～Ⅳ级相比差异具有统计学意义(%2=10.710,P=0.001)。在神经干细胞、裸小鼠移植瘤、胶质瘤干细胞球体表达率为100%。在多种正常组织中亦有不同程度的表达。在胶质瘤临床标本中ABCG2阳性细胞呈亲血管分布。结论:ABCG2在胶质瘤干细胞、恶性程度高的胶质瘤组织标本和移植瘤组织中高表达,并且呈亲血管分布。
文摘目的:明确结直肠癌组织中ABCG2(ATP-binding cassette superfamily G member 2,ABCG2)的表达及其与患者临床病理特征、以伊立替康(CPT-11)为基础化疗疗效的相关性,从而为结直肠癌患者实现个体化治疗提供理论依据。方法:筛选1996年1月至2011年12月于北京大学肿瘤医院行CPT-11化疗的晚期结直肠癌患者,收集患者完整病史资料及肿瘤组织样本。用免疫组织化学的方法检测样本中ABCG2蛋白表达情况。分析ABCG2蛋白表达与患者临床病理特征、CPT-11化疗疗效的相关性。结果:1)免疫组织化学染色显示ABCG2在结直肠癌组织中表达阳性率达93.2%,癌旁正常肠黏膜ABCG2蛋白阳性表达率为43.6%,癌组织较癌旁正常黏膜组织的表达水平明显增高(P<0.05)。ABCG2表达与患者年龄、性别、病理分化程度、病变部位、肝转移均无明显相关性。2)ABCG2蛋白表达与CPT-11化疗疗效无显著相关(P>0.05)。结论:在应用伊立替康为基础方案化疗的结直肠癌患者中,癌组织中ABCG2蛋白表达水平与患者化疗疗效无明显相关。
